Pages that link to "Q37827451"
Jump to navigation
Jump to search
The following pages link to Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. (Q37827451):
Displaying 36 items.
- Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives (Q26826817) (← links)
- Antibody Therapies in Cancer (Q31104000) (← links)
- Targeted inhibition of VEGF receptor 2: an update on ramucirumab (Q34040956) (← links)
- Biomarkers for anti-angiogenic therapy in cancer. (Q34695003) (← links)
- Anti-cadherin-17 antibody modulates beta-catenin signaling and tumorigenicity of hepatocellular carcinoma (Q34988368) (← links)
- TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis. (Q35622461) (← links)
- Molecularly Targeted Therapy of Human Hepatocellular Carcinoma Xenografts with Radio-iodinated Anti-VEGFR2 Murine-Human Chimeric Fab (Q35662815) (← links)
- Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial. (Q35798947) (← links)
- Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. (Q35895174) (← links)
- IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA. (Q35992493) (← links)
- Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A (Q36629386) (← links)
- DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo (Q36644256) (← links)
- Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike? (Q36936900) (← links)
- A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer (Q37258981) (← links)
- Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro (Q37501825) (← links)
- Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer (Q37874750) (← links)
- Tanibirumab (TTAC-0001): a fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2). (Q37930531) (← links)
- Management of advanced gastric cancer. (Q37989161) (← links)
- Therapeutic targeting of VEGF in the treatment of glioblastoma (Q38033241) (← links)
- Monoclonal antibodies in gastrointestinal cancers. (Q38084684) (← links)
- Ramucirumab for metastatic gastric or gastroesophageal junction cancer: results and implications of the REGARD trial. (Q38241985) (← links)
- Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor (Q38498207) (← links)
- VEGF involvement in psoriasis (Q38648336) (← links)
- Targeted therapies in gastric cancer treatment: where we are and where we are going. (Q38731943) (← links)
- Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study (Q38823193) (← links)
- Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis. (Q39368829) (← links)
- A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy (Q41574359) (← links)
- Expression, purification, and characterization of a diabody against the most important angiogenesis cell receptor: Vascular endothelial growth factor receptor 2. (Q42226546) (← links)
- Antiangiogenesis therapy in the treatment of metastatic colorectal cancer (Q42402968) (← links)
- New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness (Q47221234) (← links)
- Evaluation of short-term effectiveness of eight targeted agents combined with chemotherapy for treating esophageal-gastric junction adenocarcinoma: A network meta-analysis. (Q48124426) (← links)
- A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer. (Q52597561) (← links)
- Downregulation of KDR expression induces apoptosis in breast cancer cells. (Q54325504) (← links)
- Trends and Challenges in Tumor Anti-Angiogenic Therapies (Q90194802) (← links)
- Novel human Ab against vascular endothelial growth factor receptor 2 shows therapeutic potential for leukemia and prostate cancer (Q90443920) (← links)
- Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma (Q92989291) (← links)